Pharma feed

N
Johnson & Johnson
Seeking Alpha· 26 Nov 2020

Johnson & Johnson: A Visionary Company (NYSE:JNJ)

In the past few quarters, Johnson & Johnson struggled a bit and especially the medical devices business was affected by COVID-19. But Johnson & Johnson is a great business due to its status as dividend king, its recession-proof business and wide economic moat.

  • Johnson & Johnson
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
FirstWord Pharma· 26 Nov 2020

Tarus Therapeutics Appoints Brian Schwartz as Interim Chief Medical Officer and Head of the Scientific Advisory Board

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced that Dr. Brian Schwartz, M.D. has joined the company as Acting Chief Medical Officer and Head of the Scientific Advisory Board (SAB).Dr. Schwartz was Chief Medical Officer at ArQule from 2008, and also Head of Research & Development from 2013, until the company's acquisition by Merck in 2020 for $2.7 billion.

  • ArQule Inc
  • Merck & Co., Inc.
  • Management Changes
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
Ynetnews· 26 Nov 2020

'First COVID vaccine shipment could arrive in Israel by December'

The first shipment of coronavirus vaccines could arrive in Israel as early as December, said the Health Ministry chief on Wednesday. Follow Ynetnews on Facebook and Twitter Israel last week signed a deal for vaccine purchase with UK-based pharmaceutical giant AstraZeneca, following a deal with U.S. company Pfizer a week earlier after it announced its vaccine is 90% effective.

  • Pfizer Inc.
  • AstraZeneca PLC
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
FirstWord Pharma· 26 Nov 2020

Panama says will buy 3 mln Pfizer, BioNTech Covid-19 vaccine doses

Panama’s government said Wednesday that it has signed a deal with Pfizer and BioNTech to purchase 3 million COVID-19 vaccine doses, as reported by Fidelity.The government said the doses will be distributed during 2021 pending clinical success and local regulatory authorization. To read more articles, .

  • Pfizer Inc.
  • Biontech AG
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Moderna Inc
Moneycontrol· 26 Nov 2020

Coronavirus Essential podcast | Home Ministry issues fresh COVID-19 guidelines; vaccine front-runners Moderna and AstraZeneca gear up to vaccinate the world

On November 25, the Union Home Ministry released fresh guidelines for COVID-19 surveillance and containment which will come into effect from December 1. Meanwhile, Moderna and AstraZeneca are working neck to neck to roll out their respective vaccines as soon as possible.

  • Moderna Inc
  • AstraZeneca PLC
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
MarketScreener· 25 Nov 2020

Pfizer : Congress braces for Biden's national coronavirus strategy

WASHINGTON (AP) — Congress is bracing for President-elect Joe Biden to move beyond the Trump administration’s state-by-state approach to the COVID-19 crisis and build out a national strategy to fight the pandemic and distribute the eventual vaccine.

  • Pfizer Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Bayer AG
Bnnbloomberg· 25 Nov 2020

Bayer considers selling smaller crop-care assets

Bayer AG is considering selling some smaller crop-care brands as Chief Executive Officer Werner Baumann prunes the company’s portfolio and deals with mounting litigation costs, people familiar with the matter said. The German drugs and chemicals maker is reviewing assets deemed peripheral to its core pesticide and seed operations, the people said, asking not be identified discussing confidential information.

  • Bayer AG
  • Asset Buy/Sale
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
Business Today· 25 Nov 2020

AstraZeneca's COVID vaccine efficacy unclear; emergency approval likely by Jan: Nomura

AstraZeneca's recent results regarding Phase III clinical trials of its COVID-19 vaccine is a "bit unclear on the efficacy" as there is too much divergence between two cohorts, says Japanese research firm Nomura. The agency said that more data would be required to establish higher efficacy.

  • AstraZeneca PLC
  • Clinical Trials
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
Investorideas· 25 Nov 2020

Johnson & Johnson, Pfizer, and Merck Lost $3.5B in Combined YTD Revenue

November 25, 2020 (Investorideas.com Newswire) The coronavirus pandemic put enormous pressure on the healthcare industry, forcing pharmaceutical giants to roll out clinical trials for a COVID-19 vaccine at breakneck speed. At the same time, significant changes in demand, research and development processes, and regulation revisions amid the coronavirus crisis cut down revenues of the biggest players in the market and slowed down the growth of the entire pharmaceutical industry.

  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Clinical Trials
  • News Articles
  • News and Other Websites
Twitter· 25 Nov 2020

Please join us for the next webinar in our Innovations in Bayesian Clinical Trials, Virtual Symposium, presented by Professor Peter Mueller. Register here: https://t.co/mWPYlKd29i #Bayesian #clinicaltrials #oncology #Novartis

Innovations in Bayesian Trials Symposium & Interactive Workshop
Abstracts Bayesian Statistics and FDA Regulatory Acceptability, Greg Campbell, PhD, Former Director of Biostatistics, U.S. Food and Drug Administration In the United States Bayesi…
  • Novartis AG
  • Cytel Corporation
  • Events
  • Clinical Trials
  • Social Updates
  • Twitter
N
AstraZeneca PLC
Morningstar· 25 Nov 2020

Today's Logistics Report: Building Vaccine Supply Chains; Delivery's Uphill Climb; Farming Looks Up

By Paul Page Sign up: With one click, get this newsletter delivered to your inbox. AstraZeneca PLC has built a formidable supply chain behind its bid to join the front-runners racing to deliver a Covid-19 shot .

  • AstraZeneca PLC
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
The Financial Express· 25 Nov 2020

GSK Consumer forays into denture care segment in India with launch of Polident brand

GSK's oral health portfolio consists of Sensodyne range of toothpaste and toothbrush especially designed for people with sensitive teeth. GSK Consumer Healthcare on Wednesday said it has forayed into specialised denture care category in India with the introduction of Polident brand.

  • GlaxoSmithKline PLC
  • GlaxoSmithKline Consumer Healthcare Ltd
  • Business Expansion
  • New Offerings
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
India Education Diary· 25 Nov 2020

Merck Foundation and Botswana First Lady Marks International Day of Elimination of Violence Against Women by Starting Poster Contest to STOP GBV

Gaborone:Merck Foundation, the philanthropic arm of Merck Germany, marks the International Day for the Elimination of Violence Against Women with the announcement of “Stop GBV” Poster Contest in partnership with H.E Mrs. NEO JANE MASISI, The First Lady of Botswana and Ambassador of Merck More Than A Mother, with the aim to prevent gender-based violence and child abuse in the country.

  • Merck & Co., Inc.
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Benzinga· 25 Nov 2020

What Does Johnson & Johnson's Debt Look Like?

Over the past three months, shares of Johnson & Johnson (NYSE: JNJ) decreased by 6.13%. Before we understand the importance of debt, let us look at how much debt Johnson & Johnson has. Johnson & Johnson's Debt Based on Johnson & Johnson’s balance sheet as of October 23, 2020, long-term debt is at $32.68 billion and current debt is at $5.08 billion, amounting to $37.76 billion in total debt.

  • Johnson & Johnson
  • Capital Refinance/Restructure
  • News Articles
  • News and Other Websites
N
Astellas Pharma
FirstWord Pharma· 25 Nov 2020

Astellas Launches a “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website

Astellas Pharma Inc. ("Astellas") has launched a "Contact for Potential Acquisition of Astellas' R&D programs" section on its corporate website. This section was developed to recruit potential parties who wish to acquire Astellas' R&D programs that were terminated for strategic reasons.

  • Astellas Pharma
  • M&A Activities
  • New Offerings
  • News Articles
  • News and Other Websites
  • Takeda Pharmaceutical Co Ltd
  • Events
  • Social Updates
  • Twitter
N
Regeneron Pharmaceuticals Inc
World Pharma Today· 25 Nov 2020

Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA EUA

Regeneron Pharmaceuticals, Inc. announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. FDA.

  • Regeneron Pharmaceuticals Inc
  • US Food and Drug Administration
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
Yahoo· 25 Nov 2020

6.4M Pfizer COVID-19 Vaccine Doses To Be Distributed Across US Within 24 Hours Of FDA Approval: WaPo

Over six million doses ofPfizer Inc’s(NYSE:PFE) COVID-19 vaccine could be distributed within 24 hours of it being given the go-ahead by the United States Food And Drug Administration, The Washington PostreportedTuesday.What Happened:The vaccine’s 6.4 million doses would be sent across communities and the first shots are expected to be given to front-line health-care workers, according to the Post.

  • Pfizer Inc.
  • US Food and Drug Administration
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
FiercePharma· 25 Nov 2020

Feds on COVID-19 mRNA vaccine distribution: Pfizer's dry runs predict a 'very doable process'

What will it take to distribute the first 6.4 million doses of Pfizer’s COVID-19 mRNA vaccine, if all goes according to plan and they ship in mid-December? Alex Azar, secretary of health and human services, acknowledged during a press conference Tuesday that the logistics—which include the need for ultra-cold storage—will be far from easy.

  • Pfizer Inc.
  • Regulatory and Legal
  • Press Releases
  • News and Other Websites
N
GlaxoSmithKline PLC
The Economic Times· 25 Nov 2020

GSK launches global oral care brand Polident in India

XiaomiAstraZenecaMuthoot FinanceDHFLMukesh AmbaniIndian Airlines newsTelecom newsBanking newsFinance newsAuto News

  • GlaxoSmithKline PLC
  • New Offerings
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
Inquirer· 25 Nov 2020

AstraZeneca eyes clinical trials for its COVID-19 vaccine in PH

MANILA, Philippines — British drug maker AstraZeneca has already submitted the necessary documents to Philippine health authorities to secure approval in conducting clinical trials for its COVID-19 vaccine in the country. Health Undersecretary Maria Rosario Vergeire said this Wednesday, just days after AstraZeneca announced that its COVID-19 vaccine can be 90% effective.

  • AstraZeneca PLC
  • Clinical Trials
  • News Articles
  • News and Other Websites
N
US Food and Drug Administration
Business Standard· 25 Nov 2020

Alembic Pharma gets USFDA approval for testosterone gel

The drug major on Wednesday announced that its joint venture, Aleor Dermaceuticals (Aleor), has received US drug regulator's tentative approval for testosterone gel.Alembic Pharma in an exchange filing said the tentatively approved ANDA is therapeutically equivalent to the reference listed drug product, AndroGel of AbbVie Inc. Testosterone gel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

  • US Food and Drug Administration
  • AbbVie Inc
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
Bangkok Post· 25 Nov 2020

Covid vaccine contract signing Friday

Covid vaccine contract signing Friday The National Vaccine Institute will sign a 6-billion-dollar forward contract for Covid-19 vaccine with British-Swedish producer AstraZeneca on Friday. Prime Minister Prayut Chan-o-cha will preside over the ceremony, deputy government spokesperson Traisuree Taisaranakul said on Wednesday.

  • AstraZeneca PLC
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
Wired· 25 Nov 2020

The AstraZeneca Covid Vaccine Data Isn't Up to Snuff

The makers of a third coronavirus vaccine announced positive results in clinical trials on Monday, setting off yet another round of excited news reports. This one, produced by a partnership between a University of Oxford research institute, its spinout company Vaccitech, and the pharmaceutical company AstraZeneca, does not need to be stored at freezing temperatures and would be cheaper and easier to produce than the high-efficacy vaccines produced by BioNTech-Pfizer and Moderna.

  • AstraZeneca PLC
  • Partnerships and Alliances
  • Clinical Trials
  • News Articles
  • News and Other Websites
Takeda Pharmaceutical Co Ltd
Arrowheadpharma· 25 Nov 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 25, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020 , has now closed.

  • Takeda Pharmaceutical Co Ltd
  • Arrowhead Pharmaceuticals
  • Partnerships and Alliances
  • Press Releases
  • Company Websites
1 2 3 4 5